Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2015 by Memorial Sloan Kettering Cancer Center
Sponsor:
Collaborators:
National Comprehensive Cancer Network
GlaxoSmithKline
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01682213
First received: September 6, 2012
Last updated: July 21, 2015
Last verified: July 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: September 2016
  Estimated Primary Completion Date: September 2016 (Final data collection date for primary outcome measure)